Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL)

Diabetes Mellitus Clinical Trial

— TBL  

Official title:

Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03278483
• Other study ID #: 1341
• Status: Completed
• Phase: Phase 4
• Start date: February 28, 2019
• Est. completion date: February 28, 2019

Study information

• Verified date: April 2019
• Source: Instituto Nacional de Salud Publica, Mexico
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Researchers will evaluate the efficacy, toxicity, adherence and cost effectiveness of treatment with isoniazid or rifampicin in patients with diabetes mellitus type two (DM2) and latent TB (LTB).

This is a collaborative study with participation from three national institutes (Instituto Nacional de Salud Pública (INSP), Instituto Nacional de Enfermedades Respiratorias (INER) and the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran (INCMNSZ)).

The study will take place in the VII sanitary jurisdiction of Orizaba and the INCMNSZ that has the necessary infrastructure and human resources. Researchers will evaluate 3000 patients with diabetes using a standardized questionnaire and a tuberculin skin test (TST) test. Eligible patients will be invited to participate and from those that agree to participate and sign a written informed consent we will obtain clinical, epidemiological, nutritional and metabolic information. Patients with altered liver function tests will be excluded.

Description:

This study is a randomized control trial, with two parallel arms, fixed assignment, fixed sample size and in two study sites. Participants will be assigned 1:1 to receive one of the two treatment regimens: isoniazid for 6 months or rifampicin for 3 months. The assignment will be fixed because the covariates that predict the clinical outcome and the accumulated outcome of participants will not affect treatment assignment. In patients that the Michigan evaluation identifies as having neuropathic changes researchers will perform an electroneurography in order to identify the degree of neuropathy if any. This will be performed in the neurophysiology lab of the INCMNSZ. An independent comity will monitor adverse events.

Sample size It is necessary to include 193 participants, for each arm; this includes a 20% increase to compensate loss during follow up. This will provide a power equal or higher than 80% considering an alpha of 0.05 (.25 at two tails) in order to answer to each one of the following objectives.

Latent tuberculosis treatment with isoniazid is the gold standard and given its efficacy it would not be ethical to propose a placebo group. Researchers hypothesize that treatment with rifampicin will not be inferior in efficacy (measured using the response of biomarkers) and will be equivalent in toxicity to that observed with isoniazid treatment.

Subjects will be asked to attend on the 15th and 30th of the month and then once a month till the end of treatment. In case a patient does not assist, researchers will carry out a home visit.

Clinical, microbiological and metabolic evaluation

Researchers will apply a validated questionnaire that explores sociodemographic, epidemiological and clinical information as well as a questionnaire developed by the researchers that captures information of DM2 long term complications. The Michigan questionnaire will be applied using the NCI-CTC scale in version 3 for neuropathic symptoms as well as an evaluation with a Semmes-Weinstein monofilament of 5.07/10gr in 4 points of the sole of each foot:

• Distal phalange of the 1st toe, base of the 1st metatarsal and base of the 3rd metatarsal

• Base of the 5th metatarsal In a subsample researchers will carry out an electroneurography study in order to measure and document the level of likely damage as an adverse event.

Tuberculin Skin Test (TST) In patients with DM2 researchers will apply TST using the Mantoux technique. Reactivity will be measured with the diameter of the induration at 48 and 72 hours. Patients with a TST>10mm will be randomized to the trail.

Chest X ray All patients with a positive TST will have a chest X ray taken which will be evaluated by a pulmonologist in order to exclude millar TB.

All patients will be tested for hematic cytology, glucose, glycosylated hemoglobin, and creatinine and liver tests. All lab tests will be carried out using standardized methods that are commercially available.

All documentation of clinical evaluations will be included in the patient's medical chart. These will be safeguarded by the main researcher and confidentiality will be protected at all times.

TB tests During follow up respiratory symptoms will be evaluated. Patients with respiratory symptoms of more than 2 weeks will be asked to give 3 sputum samples in order to analyze for acid fast bacilli (AFB) and Mycobacterium tuberculosis (MTB) culture using standardized methods.

All samples will be identified with a code that links the sample with clinical and epidemiological data. Researchers have established a system that prevents unauthorized people from accessing the samples and personal data.

Field work Personnel have been trained in the good clinical practice course which Works very closely with the health centers. Activities are monitored by supervisors that have been trained to insure the coordination of activities and quality control.

Independent comity for monitoring adverse events For this study researchers will integrate an independent comity to monitor adverse events, which will revise all adverse events and will give follow up.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 396
• Est. completion date: February 28, 2019
• Est. primary completion date: February 28, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Type 2 diabetes mellitus (DM2) diagnosed based on the National Official Norm

2. respiratory symptoms

3. Tuberculin Skin Test (TST) >10mm of induration

4. chest X ray without pleural, lung or mediastinal lesions

5. hemoglobin < 8 gm/dl

6. platelets > 60,000 per microliter

7. bilirubin < 2.5 mg/dl

8. Aspartate aminotransferase (AST) , Glutamic oxalacetic transaminases (SGOT) and alkaline phosphatase less than twice the normal value

9. negative pregnancy test

10. negative Human immunodeficiency virus infection test (HIV test)

11. signed written informed consent.

Exclusion Criteria:

1. Attending selected cites

2. Respiratory symptoms defined as cough with or without sputum for more than 2 weeks

3. Evidence or clinical suspicion of active tuberculosis (TB)

4. Current treatment with antituberculous drugs

5. History of having received more than one month's treatment for latent Tuberculosis (LTB) or antituberculous drugs

6. Hypersensitivity or intolerance to isoniazid or rifampicin

7. Active hepatopathy

8. Grade III or higher peripheral neuropathy

9. Chronic alcohol ingestion

10. Contacts of patients with isoniazid or rifampicin drug resistance

Related Conditions & MeSH terms

• Diabetes Mellitus
• Tuberculin (Skin Test) Positive

Intervention

Drug:
• Isoniazid 300 mg Oral Tablet
Isoniazid tablets 300mg daily plus pyridoxine 50mg daily
• Rifampin 600 mg Oral Tablet
Rifampin capsules 600mg daily

Locations

Country	Name	City	State
Mexico	Instituto Nacional de Ciencias Medicas y Nutrición	Mexico City

Sponsors (3)

Lead Sponsor	Collaborator
Instituto Nacional de Salud Publica, Mexico	Instituto Nacional de Ciencias Medicas y Nutrición, Instituto Nacional de Enfermedades Respiratorias

Country where clinical trial is conducted

Mexico, 

References & Publications (1)

Torres M, García-García L, Cruz-Hervert P, Guio H, Carranza C, Ferreyra-Reyes L, Canizales S, Molina S, Ferreira-Guerrero E, Téllez N, Montero-Campos R, Delgado-Sánchez G, Mongua-Rodriguez N, Sifuentes-Osornio J, Ponce-de Leon A, Sada E, Young DB, Wilkins — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of treatment with rifampicin compared to efficacy of treatment with isoniazid	Researchers will measure with ELISA in vitro production of interferon gamma of peripheric mononuclear cels as a response to stimuli by RV0849 and RV1737 antigens. The cut of value is of >100pg/ml.	Up to 18 months
Primary	Toxicity (neuropathy)	Neurological alterations will be assessed using the Michigan questionnaire and in a subsample they will evaluate neuropathy using electroneurography.	Up to 6 months
Primary	Adherence	Counting the number of administered pills, adequate adherence is more than 80% of administered pills.	Up to 6 months
Primary	Toxicity (liver function)	Liver function tests	Up to 6 months